Medtronic (NYSE:MDT) announced today that it launched its adaptive deep brain stimulation (aDBS) system in India.
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease For 30 years, people with Parkinson's disease ...
Personalized, adaptive deep brain stimulation (aDBS) is safe and effective for controlling motor symptoms over 10 months in adults with Parkinson’s disease (PD), new research showed. The ADAPT-PD ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
Medtronic introduces Adaptive Deep Brain Stimulation system to aid Parkinson's disease patients, enhancing treatment options ...
The aDBS system uses BrainSense technology, which has been approved by the U.S. Food and Drug Administration (FDA) ...
NEW DELHI, IN / ACCESS Newswire / April 27, 2026 / Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation o ...
Global health-tech major Medtronic has launched its Adaptive Deep Brain Stimulation (aDBS) system in India to improve the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results